DNA testing can predict ineffective chemotherapy treatment for colon cancer


Researchers from the Netherlands Cancer Institute have demonstrated that it is possible to predict which patients with metastatic colon cancer will not benefit from the life-prolonging chemotherapy regimen FTD/TPI using a DNA test. The findings can lead to the careful selection of patients with tumors that are insensitive to this type of chemotherapy, sparing them from unnecessary treatment with unpleasant side effects. It would be the first time that a genetic test is used in daily patient care to predict the outcome of a specific chemotherapy treatment. The study results were published in Nature Medicine.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.